RUSH UNIVERSITY MEDICAL CENTER Patent applications |
Patent application number | Title | Published |
20160093093 | Kinematic Analysis based on MRI Bone Marrow Signals - A method of a measuring kinematic parameter in a subject is provided. The method includes obtaining a first magnetic resonance (MR) image set of a bone marrow segment of the subject in a first position and obtaining a second MR image set of the bone marrow segment of the subject in a second position where the second position different from the first position. The method further includes registering the first image set with the second image set and measuring a kinematic parameter. | 03-31-2016 |
20160022540 | Delivery Device and Storage System for Oropharyngeal Administration of Mother's Colostrum and Milk - A delivery system and method for storing and delivering colostrum or milk to an infant are provided. In one aspect, the system includes a syringe for delivering a dose of colostrum or milk, a swab container, and a swab. The swab is contained in the swab container and the swab container connected to the syringe. In another aspect, the delivery system includes a plurality of syringes for delivering a dose of colostrum or milk and a storage container for storing the plurality of syringes having the colostrum or milk therein. The method includes loading a first syringe with a dose of colostrum or milk and placing the loaded first syringe in a first slot in a storage container. The method further includes loading a second syringe with a dose of colostrum or milk and placing the loaded second syringe in a second slot in the storage container. | 01-28-2016 |
20160015743 | METHODS FOR TREATING CANCER - Disclosed herein are methods for treating cancer, such as a cyclin D1-overexpressing cancer, including administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an agent that mediates downregulation of cyclin D1 and/or increases sumoylation of cyclin D1. | 01-21-2016 |
20150313863 | Composition and Method for Treating Neuronal Ceroid Lipofuscinosis - Provided herein are methods for treatment of a neurodegenerative disease, such as neuronal ceroid lipofuscinosis including administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an agent that mediates upregulation of TPP 1. | 11-05-2015 |
20150275299 | miRNAs as Novel Therapeutic Targets and Diagnostic Biomarkers for Parkinsons Disease - The disclosure provides pharmaceutical compositions including an oligonucleotide that down-regulates the over-expression of at least one miRNA of SEQ ID NOs: 1-283. The oligonucleotide may be complementary to the nucleotide sequence of at least one of SEQ ID NOs: 1-283, or hybridizes under stringent conditions to a nucleotide sequence of at least one of SEQ ID NOs: 1 -283. Further provided are methods of diagnosing Parkinson's Disease (PD) in a subject. The methods may include detecting the level of expression of at least one miRNA of SEQ ID NOs: 1-283 in a biological sample from the subject, and comparing the level of expression in the sample to the level of expression in a reference. Further provided are methods for treating, preventing, or reducing the risk of PD. Kits are also provided. | 10-01-2015 |
20150184162 | Antisense Oligonucleotides Against Neutral Sphingomyelinase and Neutral Sphingomyelinase Inhibitor GW4869 for Degenerative Neurological Disorders - Alzheimer's disease (AD) is the most common human neurodegenerative disease of the CNS resisting in progressive neuronal death and memory loss. Despite intense investigations, no effective therapy is available to stop its onset or halt its progression. It was discovered that antisense oligonucleotide against neutral sphingomyelinase and GW | 07-02-2015 |
20140314710 | IL-12 P40 Monomer, Monoclonal Antibody Against P40 Homodimer and the Combination of the Two for Autoimmune Disease Treatment - A novel approach to discover new drugs against MS and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (IL-12), the p40 monomer (p40), the p40 homodimer (p40 | 10-23-2014 |
20140309715 | Energy-Releasing Carbon Nanotube Transponder and Method of Using Same - An energy-releasing carbon nanotube transponder comprising a nanocapacitor connected to at least one carbon nanotube and method of using same are described. An adjustable amount of electric energy is stored within the nanocapacitor so that the energy-releasing carbon nanotube transponder delivers either a biologically destructive or a biologically non-destructive electrical charge to target cells in response to biological, chemical or electrical stimuli. An optional biocompatible coating onto the outer surface of the carbon nanotube transponder improves cellular targeting, cellular binding or body tolerance towards the carbon nanotube transponder. Optionally, a molecular label attached to at least one carbon nanotube allows for in vivo tracking of the carbon nanotube transponder. The targeted release of electric energy from the carbon nanotube transponder can, for example, destroy cancer cells in cancer patients, or control the flux of electric wave within a cellular tissue to treat cardiac and/or epileptic patients. | 10-16-2014 |
20140274772 | BIOMARKER PANEL FOR DETECTING LUNG CANCER - A method and a kit for assessing risk of lung cancer versus benign disease in a subject are provided. The method includes obtaining a biological sample from the subject and determining a measurement for a panel of biomarkers in the biological sample. The panel includes at least two biomarkers selected from the group consisting of IL-6, IL-1ra, IL-10, SDF-1α+β, TNF-α, MIP-1α, sIL-2Rα, CA-125, sE-Selectin, Eotaxin, sEGFR, MMP-2, OPN, MCP-1, CRP, sICAM-1 and CYFRA 21.1. The method further includes comparing the measurement to a reference profile for the panel of biomarkers, sorting the subject into a group and determining whether the subject is at risk for lung cancer based on the group. | 09-18-2014 |
20140179629 | SLOWLY DIGESTING STARCH AND FERMENTABLE FIBER - Compositions which provide slowly digestible starch and a source of fermentable dietary fiber. Microparticles in which starch is entrapped in a crosslinked matrix to provide dietary benefit. Such microparticles are used to deliver glucose to targeted regions in the small intestine for beneficial physiological effects, and fermentable dietary fiber to the colon to improve colon health and to treat diseases of the colon. Microparticles can be employed to selectively deliver fermentable dietary fiber to targeted portions of the colon. | 06-26-2014 |
20140148891 | VESSEL BIFURCATION STENT DEPLOYMENT SYSTEM WITH ZIPPERED CATHETERS - A bifurcated catheter, which can deploy a bifurcated stent constructed as a single piece into a bifurcated vessel, is disclosed. The system may have two main parts—a y-shaped catheter with a splittable seam, and a custom made stent, which can be deployed with the bifurcated catheter. The disclosed bifurcated catheter permits a physician or operator to stent a vessel at a bifurcation of the vessel. | 05-29-2014 |
20140147856 | Intestinal Permeability Assay for Neurodegenerative Diseases - A method of identifying a subject at risk of developing or having a neurodegenerative disorder is provided. The method includes obtaining a biological sample from the subject and assaying a level of a marker of intestinal permeability in the sample. The method further includes comparing the subject's level to a control level for the marker of intestinal integrity and identifying the subject having an increased intestinal permeability relative to the control intestinal permeability as having an increased risk of developing or having a neurodegenerative disorder. A method of monitoring the efficacy of a treatment for a neurodegenerative disorder is also provided. | 05-29-2014 |
20140121235 | Method for Treating S6K-Overexpressing Cancers - Disclosed herein are methods for treating an S6K-overexpressing cancer, comprising administering a therapeutically effective amount of leflunomide to a subject in need thereof. | 05-01-2014 |
20140107626 | ANCHORING FOR NON-RETAINABLE FOREIGN OBJECTS - A kit and/or method for use during surgery is configured to decrease the risk of accidental retention of foreign objects, such as surgical items or medical devices, used in surgery inside of a patient after the surgery is completed. Specifically, illustrative kits may include, but not be limited to, a combination of one or more foreign objects, an anchoring member attached to a point outside of the patient or surgical field, and at least one or more connection members connecting the foreign objects to the anchoring member. Illustrative methods may include, but not be limited to, anchoring one or more foreign object by one or more connection members, wherein a first end of each connection member is attached to the foreign object, and a second end of each connection member is attached to a junction member; attaching the junction member to an anchoring member; and attaching the anchoring member to a structure that is outside the patient or surgical field. | 04-17-2014 |
20140038223 | CRK-A NOVEL TARGET FOR CANCER THERAPY - This disclosure identifies a novel apoptotic compensatory proliferation signaling complex (ASCS) involving ExoT's cellular target, Crk1. This disclosure demonstrates that in cells induced to undergo apoptosis, Crk1 forms globular complexes which associate with plasma membrane in the apoptotic cell and are released from the dying cell to its healthy neighbor, inducing it to proliferate. ExoT prevents the ACSC assembly while inducing apoptosis, indicating that apoptotic program cell death and compensatory proliferation are distinct and can be uncoupled from each other. Without being bound to any particular theory, it is believed that Crk1 functions as a scaffold for the ACSC assembly and that its ADP-ribosylation by ExoT interferes with this process while resulting in anoikis apoptotic cell death. | 02-06-2014 |
20130331436 | MICRORNAS AS NEW THERAPEUTIC TARGETS FOR THE PREVENTION AND/OR TREATMENT OF RETINOPATHY - Methods and compositions are disclosed to identify plasma and vitreous microRNA (miRNA) signatures of diabetic retinopathy (DR), and then as diagnostic biomarkers for the onset and progression of DR. | 12-12-2013 |
20130225442 | Lung Cancer Tests - Methods for the diagnosis of lung cancer and more specifically, non-small cell lung cancer are described. An assortment of biomarkers with diagnostic or prognostic value for non-small cell lung cancer (NSCLC) are used to establish a multi-analyte serum test capable of diagnosing patients with lung cancer. A first method assesses an elevated level of expression of one or more nucleic acids, a polypeptide encoded by the nucleic acid or an autoantibody to said polypeptide. An alternative method includes (a) determining whether or not a patient has NSCLC versus a non-NSCLC lung cancer, and (b) classifying the patient as susceptible to specific treatments if the patient has a NSCLC profile and classifying the patient as not susceptible to a specific treatment if the patient does not have a NSCLC profile. | 08-29-2013 |
20130178442 | GENE EXPRESSION PROFILES AND PRODUCTS FOR THE DIAGNOSIS AND PROGNOSIS OF POSTINJURY SYNOVITIS AND OSTEOARTHRITIS - Associations between inflammation and pain/function scores were tested by univariate and multivariate analyses. Gene expression was analyzed by microarray and real-time PCR comparing patients with and without synovial inflammation. Synovitis was present in 43% of patients presenting for arthroscopic menisectomy. Inflammation was associated with pre-operative Lysholm scores, independent of age, gender, and BMI. Synovial RNA microarray analysis revealed 260 genes differently expressed ≧2-fold between patients with and without synovitis. A chemokine signature identified in the “inflammatory” biopsies was confirmed by real-time PCR. In conclusion, in patients presenting for arthroscopic menisectomy, synovitis is associated with symptoms. Comparison of expression patterns revealed enrichment of chemokines associated with cellular recruitment and activation in patients with synovitis. These chemokines may represent targets for therapeutic intervention to reduce inflammatory symptoms in patients with meniscal injury. | 07-11-2013 |
20120252036 | DIAGNOSTIC TESTS FOR ABNORMAL OVARIAN CONDITIONS - Methods and compositions, and a kit for diagnosing ovarian disorders including autoimmunity and ovarian cancer. Ovarian autoimmunity is associated with unexplained infertility or idiopathic premature ovarian failure that occurs in the absence of polyglandular disease. Methods and composition described herein are used to detect ovarian autoimmunity before the onset of ovarian dysfunction. Thus, those individuals are identified who would benefit from therapy to maintain, as well as restore, ovarian function. | 10-04-2012 |
20110232133 | JOINT LOAD REDUCING FOOTWEAR - Footwear including a flexible sole having a series of flexure zones positioned to correspond to primary joint axes of the human foot approximating the characteristics of a bare foot in motion. | 09-29-2011 |
20110185486 | Support for Wall Mounted Toilets - A support platform for wall mounted toilets is described. The platform attaches easily under the toilet and contains bolts and feet for adjustment. The platform provides support to wall mounted toilets so that persons of weight greater than the rated load of the wall mounted toilet can use the toilet in comfort and safety. It is removable for use in different bathrooms, easily transported and can be sterilized where bacterial or viral contamination is a concern. | 08-04-2011 |
20110153365 | SYSTEM AND METHOD OF MANAGING AND DOCUMENTING LACTATION DATA - A system and method of managing and documenting lactation data includes inputting patient lactation data, retrieving, editing, creating, or updating a database to include the patient lactation data in real time, and storing the patient lactation data in a database which can be centrally located to facilitate integration with other medical records. | 06-23-2011 |
20100274304 | METHOD AND DEVICE TO MANAGE FREEZING OF GAIT IN PATIENTS SUFFERING FROM A MOVEMENT DISORDER - The subject invention involves a device and method for treating patients with a movement disorder experiencing a sudden change in regularity of gait or akinesia, and comprising a device that detects the sudden change in regularity of gait or temporary akinesia and automatically issues a cue signal that restarts the movement. | 10-28-2010 |
20100267742 | COMBINATION TARGETED THERAPY FOR LUNG CANCER - A combination of compounds is described that target protein kinases and is more effective than the individual compounds against cancer where EGFR is upregulated and c-met is activated, for example, epithelial cell tumors, and particularly, non small cell lung carcinomas (NSCLC). | 10-21-2010 |
20100174372 | PLASTIC IMPLANT IMPREGNATED WITH A DEGRADATION PROTECTOR - A plastic implant device for a mammal that contains a rare earth metal compound tracer and a method for detecting degradation such as wear of the implanted device are disclosed. The tracer can also be present with a separate antioxidant or the tracer compound can be can be the salt of a C | 07-08-2010 |
20100143929 | DNA METHYLATION BASED TEST FOR MONITORING EFFICACY OF TREATMENT - A DNA methylation-based test for efficiency of treatments is based on a plurality of genes. The test is suitable for monitoring treatment of subjects with neurological diseases, e.g., multiple sclerosis (MS); with cancer, e.g., breast and ovarian cancer, and with other diseases for which methylation of biomarkers differs in the diseased compared to the non-diseased state. | 06-10-2010 |
20100010630 | PLASTIC IMPLANT IMPREGNATED WITH A DEGRADATION PROTECTOR - A plastic implant device for a mammal that contains a rare earth metal compound tracer and a method for detecting degradation such as wear of the implanted device are disclosed. The tracer can also be present with a separate antioxidant or the tracer compound can be can be the salt of a C | 01-14-2010 |
20080255049 | COMBINED USE OF ULTRASOUND AND GROWTH FACTORS TO STIMULATE BONE FORMATION - The combination of low intensity pulsed ultrasound with administration of an osteogenic protein or proteins or their genes enhances bone repair in mammals. This combination avoids thermal activation of tissue repair mechanisms and allows the osteogenic protein or proteins or their genes to act at the site of bone fracture or lowered bone density to enhance or accelerate bone formation, thereby improving the prognosis of a patient. The combination may be used to treat fractures, to prevent or treat osteoporosis, to improve outcomes for bone replacement and to prevent or treat bone loss due to other physiologic disorders. | 10-16-2008 |